- Home
- INMB vs CVM Comparison
INMB vs CVM Comparison
Compare INMB & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMB | CVM |
|---|---|---|
| Founded | 2015 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.3M | 32.4M |
| IPO Year | 2018 | 1996 |
Fundamental Metrics
Financial Performance| Metric | INMB | CVM |
|---|---|---|
| Price | $1.33 | $3.89 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.30 | N/A |
| AVG Volume (30 Days) | ★ 408.0K | 42.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $14,000.00 | ★ $264,033.00 |
| Revenue This Year | $264.29 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $1.21 | $0.18 |
| 52 Week High | $11.64 | $13.48 |
Technical Indicators
Market Signals| Indicator | INMB | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 37.84 | 37.95 |
| Support Level | $1.21 | $2.02 |
| Resistance Level | $1.71 | $6.71 |
| Average True Range (ATR) | 0.11 | 0.41 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 19.24 | 27.72 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.